Remarkably, IGF-1 treatment restores synaptic deficits in neurons from 22q11.2 deletion syndrome patients, a syndrome characterized by an increased risk of SZ and ASD [76], as well as in a SHANK3-deficient mouse model of autism [77]. This evidence concerns the gene IGF1 and 22q11.2 deletion syndrome.